Lucas Kohorst
@lucas
days @dcgco nights @adjacent___
Lucas Kohorst
kohor.st
On the Impossible: Why Cassava Sciences’ simufilam will fail Phase 3 clinical trials and the stock will trade to $2
The text analyzes Cassava Sciences' simufilam, predicting its failure in Phase 3 trials for Alzheimer's disease due to ineffective mechanisms, poor pharmacokinetics, and manipulative data practices.
ontheimpossible.vercel.appIf you have time to consume, you have time to create.
100 Simple Truths
The Trump coin market should resolve to "No" as per its own rules. If it doesn't, it's a serious problem.
polymarketscam.com
Best practices around creating production ready web apps with Docker Compose | Hacker News
nickjjnews.ycombinator.com
MarketVector Indexes
marketvector.com
